Europe Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity

About the Report

About the Report

Europe digital biomarkers market accounted for USD 118.0 million in 2019 and will grow by 40.3% annually over 2020-2030 owing to the rising demand for mobile health apps, elevated level of smartphone and wearable technology in healthcare amid COVID-19 epidemic.

Highlighted with 42 tables and 67 figures, this 145-page report Europe Digital Biomarkers Market 2020-2030 by System Component, Therapeutic Area, Application, Development Status, End User, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Europe digital biomarkers market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe digital biomarkers market in every aspect of the classification from perspectives of System Component, Therapeutic Area, Application, Development Status, End User, and Country.

Based on System Component, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Data Collection Tools

Digital Platforms

Mobile Apps

Desktop-based Software

Wearables

Biosensors

Data Integration Systems

Based on Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Cardiovascular Diseases

Neurodegenerative Disorders

Parkinson's Disease

Multiple Sclerosis

Alzheimer's Disease

Sleep and Movement Diseases

Psychiatric Disorders

Chronic Pain

Gastrointestinal Diseases

Diabetes

Respiratory Conditions

Other Diseases

Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Wellness

Disease Diagnosis

Personalised Medication

Drug Discovery and Development

Based on Development Status, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Novel Digital Biomarkers

Original Digital Biomarkers

Approved Digital Biomarkers

Based on End User, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Biopharmaceutical Companies & Labs

Healthcare Providers

Insurance Payers

Geographically, the following national/local markets are fully investigated:

Germany

UK

France

Netherlands

Italy

Russia

Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, Spain, Poland, Czech Republic, Slovakia, Hungary, and Romania)

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by System Component, Therapeutic Area, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Europe digital biomarkers market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

Actigraph LLC

Akili Interactive Labs

AliveCor Inc

Altoida Inc

Amgen Inc

Bayer AG

Biogen Inc

Cambridge Cognition Plc

Eli Lilly and Company

Evidation Health, Inc.

F. Hoffmann-La Roche Ltd

Fitbit Inc

GlaxoSmithKline Plc

Happify Health

Human API

IXICO Plc

Koninklijke Philips N.V.

Medical Care Corporation

Medopad Ltd

Mindstrong Health

Neurotrack Technology, Inc

Novartis International AG

Pfizer Inc.

Quanterix Corporation

Sanofi S.A.

The Takeda Pharmaceuticals Company Limited

Verily Life Sciences

Winterlight Labs Inc.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Products


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

Actigraph LLC

Akili Interactive Labs

AliveCor Inc

Altoida Inc

Amgen Inc

Bayer AG

Biogen Inc

Cambridge Cognition Plc

Eli Lilly and Company

Evidation Health, Inc.

F. Hoffmann-La Roche Ltd

Fitbit Inc

GlaxoSmithKline Plc

Happify Health

Human API

IXICO Plc

Koninklijke Philips N.V.

Medical Care Corporation

Medopad Ltd

Mindstrong Health

Neurotrack Technology, Inc

Novartis International AG

Pfizer Inc.

Quanterix Corporation

Sanofi S.A.

The Takeda Pharmaceuticals Company Limited

Verily Life Sciences

Winterlight Labs Inc.

Table of Contents

Table of Contents

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 14

1.2.6 Market Size/Share Estimation 15

1.2.7 Research Limitations 16

1.3 Executive Summary 17

2 Market Overview and Dynamics 20

2.1 Market Size and Forecast 20

2.1.1 Impact of COVID-19 on the Market 25

2.2 Major Growth Drivers 27

2.3 Market Restraints and Challenges 32

2.4 Emerging Opportunities and Market Trends 37

2.5 Porter's Fiver Forces Analysis 41

3 Segmentation of Europe Market by System Component 45

3.1 Market Overview by System Component 45

3.2 Data Collection Tools 47

3.2.1 Digital Platforms 49

3.2.2 Mobile Apps 50

3.2.3 Desktop-based Software 51

3.2.4 Wearables 52

3.2.5 Biosensors 53

3.3 Data Integration Systems 54

4 Segmentation of Europe Market by Therapeutic Area 55

4.1 Market Overview by Therapeutic Area 55

4.2 Cardiovascular Diseases 57

4.3 Neurodegenerative Disorders 58

4.3.1 Parkinson's Disease 60

4.3.2 Multiple Sclerosis 61

4.3.3 Alzheimer's Disease 62

4.4 Sleep and Movement Diseases 63

4.5 Psychiatric Disorders 64

4.6 Chronic Pain 65

4.7 Gastrointestinal Diseases 66

4.8 Diabetes 67

4.9 Respiratory Conditions 68

4.10 Other Diseases 69

5 Segmentation of Europe Market by Application 70

5.1 Market Overview by Application 70

5.2 Wellness 72

5.3 Disease Diagnosis 73

5.4 Personalised Medication 74

5.5 Drug Discovery and Development 75

6 Segmentation of Europe Market by Development Status 77

6.1 Market Overview by Development Status 77

6.2 Novel Digital Biomarkers 80

6.3 Original Digital Biomarkers 81

6.4 Approved Digital Biomarkers 82

7 Segmentation of Europe Market by End User 83

7.1 Market Overview by End User 83

7.2 Biopharmaceutical Companies & Labs 85

7.3 Healthcare Providers 86

7.4 Insurance Payers 87

8 European Market 2019-2030 by Country 88

8.1 Overview of European Market 88

8.2 Germany 91

8.3 UK 93

8.4 France 95

8.5 Netherlands 97

8.6 Italy 99

8.7 Russia 101

8.8 Rest of European Market 103

9 Competitive Landscape 105

9.1 Overview of Key Vendors 105

9.2 New Product Launch, Partnership, Investment, and M&A 109

9.3 Company Profiles 110

Actigraph LLC 110

Akili Interactive Labs 112

AliveCor Inc 113

Altoida Inc 114

Amgen Inc 115

Bayer AG 116

Biogen Inc 117

Cambridge Cognition Plc 118

Eli Lilly and Company 119

Evidation Health, Inc. 120

F. Hoffmann-La Roche Ltd 121

Fitbit Inc 122

GlaxoSmithKline Plc 123

Happify Health 124

Human API 125

IXICO Plc 126

Koninklijke Philips N.V. 127

Medical Care Corporation 128

Medopad Ltd 129

Mindstrong Health 130

Neurotrack Technology, Inc 131

Novartis International AG 132

Pfizer Inc. 133

Quanterix Corporation 134

Sanofi S.A. 135

The Takeda Pharmaceuticals Company Limited 136

Verily Life Sciences 137

Winterlight Labs Inc. 138

10 Investing in Europe Market: Risk Assessment and Management 139

10.1 Risk Evaluation of Europe Market 139

10.2 Critical Success Factors (CSFs) 142

Related Reports and Products 145


List of Figure

Figure 1. Research Method Flow Chart 11

Figure 2. Breakdown of Primary Research 13

Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15

Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17

Figure 5. Europe Digital Biomarkers Market, 2019-2030, USD mn 20

Figure 6. Category and Relationship of Traditional Biomarkers and Digital Biomarkers 21

Figure 7. Benefits and Challenges of Digital Biomarkers 23

Figure 8. Europe Biomarkers Market, 2019-2030, USD mn 24

Figure 9. Share of Digital Biomarkers in Total Biomarkers Market, 2019-2030 24

Figure 10. Impact of COVID-19 on Business 25

Figure 11. Primary Drivers and Impact Factors of Europe Digital Biomarkers Market 27

Figure 12. World 5G Traffic, 2019-2030, EB/year 30

Figure 13. Primary Restraints and Impact Factors of Europe Digital Biomarkers Market 32

Figure 14. Data Security Risk in Various User Groups of Digital Biomarkers 35

Figure 15. Pathway to Regulatory Approval of Digital Biomarkers 36

Figure 16. Investment Opportunity Analysis 38

Figure 17. Porter's Fiver Forces Analysis of Europe Digital Biomarkers Market 41

Figure 18. Breakdown of Europe Digital Biomarkers Market by System Component, 2019-2030, % of Revenue 46

Figure 19. Europe Addressable Market Cap in 2020-2030 by System Component, Value (USD mn) and Share (%) 46

Figure 20. Europe Digital Biomarkers Market: Data Collection Tools, 2019-2030, USD mn 47

Figure 21. Europe Digital Biomarkers Market: Digital Platforms, 2019-2030, USD mn 49

Figure 22. Europe Digital Biomarkers Market: Mobile Apps, 2019-2030, USD mn 50

Figure 23. Europe Digital Biomarkers Market: Desktop-based Software, 2019-2030, USD mn 51

Figure 24. Europe Digital Biomarkers Market: Wearables, 2019-2030, USD mn 52

Figure 25. Europe Digital Biomarkers Market: Biosensors, 2019-2030, USD mn 53

Figure 26. Europe Digital Biomarkers Market: Data Integration Systems, 2019-2030, USD mn 54

Figure 27. Breakdown of Europe Digital Biomarkers Market by Therapeutic Area, 2019-2030, % of Sales Revenue 56

Figure 28. Europe Addressable Market Cap in 2020-2030 by Therapeutic Area, Value (USD mn) and Share (%) 56

Figure 29. Europe Digital Biomarkers Market: Cardiovascular Diseases, 2019-2030, USD mn 57

Figure 30. Europe Digital Biomarkers Market: Neurodegenerative Disorders, 2019-2030, USD mn 58

Figure 31. Europe Digital Biomarkers Market: Parkinson's Disease, 2019-2030, USD mn 60

Figure 32. Europe Digital Biomarkers Market: Multiple Sclerosis, 2019-2030, USD mn 61

Figure 33. Europe Digital Biomarkers Market: Alzheimer's Disease, 2019-2030, USD mn 62

Figure 34. Europe Digital Biomarkers Market: Sleep and Movement Diseases, 2019-2030, USD mn 63

Figure 35. Europe Digital Biomarkers Market: Psychiatric Disorders, 2019-2030, USD mn 64

Figure 36. Europe Digital Biomarkers Market: Chronic Pain, 2019-2030, USD mn 65

Figure 37. Europe Digital Biomarkers Market: Gastrointestinal Diseases, 2019-2030, USD mn 66

Figure 38. Europe Digital Biomarkers Market: Diabetes, 2019-2030, USD mn 67

Figure 39. Europe Digital Biomarkers Market: Respiratory Conditions, 2019-2030, USD mn 68

Figure 40. Europe Digital Biomarkers Market: Other Diseases, 2019-2030, USD mn 69

Figure 41. Breakdown of Europe Digital Biomarkers Market by Application, 2019-2030, % of Sales Revenue 71

Figure 42. Europe Addressable Market Cap in 2020-2030 by Application, Value (USD mn) and Share (%) 71

Figure 43. Europe Digital Biomarkers Market: Wellness, 2019-2030, USD mn 72

Figure 44. Europe Digital Biomarkers Market: Disease Diagnosis, 2019-2030, USD mn 73

Figure 45. Europe Digital Biomarkers Market: Personalised Medication, 2019-2030, USD mn 74

Figure 46. Europe Digital Biomarkers Market: Drug Discovery and Development, 2019-2030, USD mn 75

Figure 47. Classification of Digital Biomarkers by Development Status 77

Figure 48. Breakdown of Europe Digital Biomarkers Market by Development Status, 2019-2030, % of Revenue 79

Figure 49. Europe Addressable Market Cap in 2020-2030 by Development Status, Value (USD mn) and Share (%) 79

Figure 50. Europe Digital Biomarkers Market: Novel Digital Biomarkers, 2019-2030, USD mn 80

Figure 51. Europe Digital Biomarkers Market: Original Digital Biomarkers, 2019-2030, USD mn 81

Figure 52. Europe Digital Biomarkers Market: Approved Digital Biomarkers, 2019-2030, USD mn 82

Figure 53. Breakdown of Europe Digital Biomarkers Market by End User, 2019-2030, % of Revenue 84

Figure 54. Europe Addressable Market Cap in 2020-2030 by End User, Value (USD mn) and Share (%) 84

Figure 55. Europe Digital Biomarkers Market: Biopharmaceutical Companies & Labs, 2019-2030, USD mn 85

Figure 56. Europe Digital Biomarkers Market: Healthcare Providers, 2019-2030, USD mn 86

Figure 57. Europe Digital Biomarkers Market: Insurance Payers, 2019-2030, USD mn 87

Figure 58. Breakdown of European Digital Biomarkers Market by Country, 2019 and 2030, % of Revenue 89

Figure 59. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value (USD mn) and Share (%) 90

Figure 60. Digital Biomarkers Market in Germany, 2019-2030, USD mn 91

Figure 61. Digital Biomarkers Market in UK, 2019-2030, USD mn 93

Figure 62. Digital Biomarkers Market in France, 2019-2030, USD mn 95

Figure 63. Digital Biomarkers Market in Netherlands, 2019-2030, USD mn 97

Figure 64. Digital Biomarkers Market in Italy, 2019-2030, USD mn 99

Figure 65. Digital Biomarkers Market in Russia, 2019-2030, USD mn 101

Figure 66. Digital Biomarkers Market in Rest of Europe, 2019-2030, USD mn 103

Figure 67. Growth Stage of Europe Digital Biomarkers Industry over the Forecast Period 105


List of Table

Table 1. Snapshot of Europe Digital Biomarkers Market, 2019-2030 18

Table 2. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples 22

Table 3. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets, 2019-2030 30

Table 4. World Mobile Data Traffic by Deployment Mode, 2019-2030, EB/year 31

Table 5. World Mobile Data Traffic by Device, 2019-2030, EB/year 31

Table 6. Current Challenges of Digital Biomarkers in Medical Settings 34

Table 7. Main Product Trends and Market Opportunities in Europe Digital Biomarkers Market 37

Table 8. Europe Digital Biomarkers Market by System Component, 2019-2030, USD mn 45

Table 9. Europe Digital Biomarkers Market: Data Collection Tools by Type, 2019-2030, USD mn 48

Table 10. Europe Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 55

Table 11. Europe Digital Biomarkers Market: Neurodegenerative Disorders by Type, 2019-2030, USD mn 59

Table 12. Europe Digital Biomarkers Market by Application, 2019-2030, USD mn 70

Table 13. Europe Digital Biomarkers Market by Development Status, 2019-2030, USD mn 78

Table 14. Europe Digital Biomarkers Market by End User, 2019-2030, USD mn 83

Table 15. Europe Digital Biomarkers Market by Country, 2019-2030, USD mn 90

Table 16. Germany Digital Biomarkers Market by System Component, 2019-2030, USD mn 92

Table 17. Germany Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 92

Table 18. Germany Digital Biomarkers Market by End User, 2019-2030, USD mn 92

Table 19. UK Digital Biomarkers Market by System Component, 2019-2030, USD mn 94

Table 20. UK Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 94

Table 21. UK Digital Biomarkers Market by End User, 2019-2030, USD mn 94

Table 22. France Digital Biomarkers Market by System Component, 2019-2030, USD mn 96

Table 23. France Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 96

Table 24. France Digital Biomarkers Market by End User, 2019-2030, USD mn 96

Table 25. Netherlands Digital Biomarkers Market by System Component, 2019-2030, USD mn 98

Table 26. Netherlands Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 98

Table 27. Netherlands Digital Biomarkers Market by End User, 2019-2030, USD mn 98

Table 28. Italy Digital Biomarkers Market by System Component, 2019-2030, USD mn 100

Table 29. Italy Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 100

Table 30. Italy Digital Biomarkers Market by End User, 2019-2030, USD mn 100

Table 31. Russia Digital Biomarkers Market by System Component, 2019-2030, USD mn 102

Table 32. Russia Digital Biomarkers Market by Therapeutic Area, 2019-2030, USD mn 102

Table 33. Russia Digital Biomarkers Market by End User, 2019-2030, USD mn 102

Table 34. Digital Biomarkers Market in Rest of Europe by Country, 2019-2030, USD mn 104

Table 35. Breakdown of Europe Market by Key Vendor, 2019, % 107

Table 36. Actigraph LLC: Company Snapshot 110

Table 37. Actigraph LLC: Business Segmentation 110

Table 38. Actigraph LLC: Product Portfolio 111

Table 39. Actigraph LLC: Revenue, 2016-2018, USD mn 111

Table 40. Actigraph LLC: Recent Developments 111

Table 41. Risk Evaluation for Investing in Europe Market, 2019-2030 140

Table 42. Critical Success Factors and Key Takeaways 143

You can also purchase parts of this report. Do you want to check out a section wise price list?

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022

What Our Clients Say About Us

Want the same for your business? Talk To Our Expert